do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance Therapeutic Effects of and in Neuropathic Pain: Mechanisms and Clinical Implications do not combine dpp-4 inhibitors

Studies on GHK-Cu have demonstrated various potential benefits

The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role of -glutamylcysteine synthetase and -glutamyltranspeptidase, FEBS Lett

In phase 2 trials, cagrilintide alone produced dose-dependent reductions in body weight, with participants on the highest dose (4.5 mg weekly) losing roughly 10-15% of body weight over 26 weeks

However, studies examining carnitine levels in CFS patients have been inconclusive, showing either normal (49, 50) or reduced levels (30, 40, 51, 52) for at least some acylcarnitine forms (53)

You can also reference this fact sheet from WADA for more information

10.1039/c6mt00195e Metallomics